ArticleCoordination chemistry reviews2025
Harnessing the power of nanoagents in acute kidney injury: A versatile platform for imaging and treatment.
Article in Coordination chemistry reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advances and perspectives of functional nanomaterials in scavenging reactive oxygen species for acute kidney injury.Bioactive materials · 2026Review
- Ultrasmall Ag₂Se@Mn quantum dots enable dual-modal imaging-guided early detection and antioxidant therapy of acute kidney injury.Mikrochimica acta · 2026Article
- Trimetallic Nanozyme-Embedded Smart Hydrogel Enables NIR-Controlled Bacterial Killing and Oxidative Stress Alleviation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- "Dual lock-and-key" triggered and endoplasmic reticulum targeting nanophotosensitizers for activatable Type-I photodynamic and photothermal therapies.Chemical science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Acute kidney injury (AKI), a severe complication marked by a sudden decline in renal function, is a significant public health concern with high morbidity and mortality rates. The early diagnosis and effective treatment of AKI remain challenging due to the complex etiology and pathophysiology of the disease. Nanoagents have emerged as a promising strategy for improving AKI management by enabling early detection, monitoring disease progression and enhancing treatment efficacy. This review provides a comprehensive overview of the recent advances in nanoagent-based approaches for AKI imaging and treatment. We first discuss the pathophysiological characteristics of AKI and their influence on nanoparticle targeting, accumulation, and clearance in diseased renal tissues. Next, we present a variety of nanoagent-based imaging techniques for monitoring kidney function and diagnosing AKI. We also outline the therapeutic principles of AKI and summarize the broad array of nanotherapeutic agents developed for AKI treatment. Finally, the review discusses the challenges of bringing nanoagent research into clinical use and explores future directions, emphasizing key opportunities to drive progress in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.